Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States

ABSTRACT Aims Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction‐associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency and correlates of co‐initiation. Materials and Methods This new‐user cohort study used TriNetX US Collaborative Network health records of patients first prescribed resmetirom from 14 March 2024 to 16 July 2026. Among patients without incretin prescriptions in the prior 5 years, those with an incretin prescription 0–30 days after resmetirom (co‐initiators) were compared with non‐co‐initiators using standardized mean differences (SMDs) and Mantel–Haenszel analysis stratified by overweight/obesity and Type 2 diabetes. Results Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m 2 ), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co‐initiators. Coded overweight/obesity (49.4% vs. 49.0%; SMD: 0.01) and Type 2 diabetes (30.3% vs. 33.1%; SMD: 0.06) were similar; co‐initiation was about 5% in every stratum (Mantel–Haenszel odds ratios: overweight/obesity 1.08 [95% CI: 0.80–1.46]; diabetes 1.00 [0.75–1.34]). Co‐initiators had higher mean BMI (35.3 vs. 33.0 kg/m 2 ; SMD: 0.33) and were more often prescribed metformin (27.7% vs. 19.0%; SMD: 0.21). Conclusions Because more than one‐third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed. Co‐initiation was uncommon and not clearly associated with overweight/obesity or Type 2 diabetes, despite higher BMI in co‐initiators.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-16
DOI
https://doi.org/10.1111/dom.71562
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States

Filippos Anagnostakis, Michail Kokkorakis, Ilias Papadimopoulos, Najam Gohar
Diabetes Obesity and Metabolism
Liver Disease Diagnosis and Treatment
article

Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States

Filippos Anagnostakis, Michail Kokkorakis, Ilias Papadimopoulos, Najam Gohar
article en

Abstract

ABSTRACT Aims Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction‐associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency and correlates of co‐initiation. Materials and Methods This new‐user cohort study used TriNetX US Collaborative Network health records of patients first prescribed resmetirom from 14 March 2024 to 16 July 2026. Among patients without incretin prescriptions in the prior 5 years, those with an incretin prescription 0–30 days after resmetirom (co‐initiators) were compared with non‐co‐initiators using standardized mean differences (SMDs) and Mantel–Haenszel analysis stratified by overweight/obesity and Type 2 diabetes. Results Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m 2 ), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co‐initiators. Coded overweight/obesity (49.4% vs. 49.0%; SMD: 0.01) and Type 2 diabetes (30.3% vs. 33.1%; SMD: 0.06) were similar; co‐initiation was about 5% in every stratum (Mantel–Haenszel odds ratios: overweight/obesity 1.08 [95% CI: 0.80–1.46]; diabetes 1.00 [0.75–1.34]). Co‐initiators had higher mean BMI (35.3 vs. 33.0 kg/m 2 ; SMD: 0.33) and were more often prescribed metformin (27.7% vs. 19.0%; SMD: 0.21). Conclusions Because more than one‐third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed. Co‐initiation was uncommon and not clearly associated with overweight/obesity or Type 2 diabetes, despite higher BMI in co‐initiators.

Diabetes Obesity and Metabolism
University Medical Center Groningen (NL), University of Groningen (NL), Yale University (US), Jena University Hospital (DE), Artificial Intelligence in Medicine (Canada) (CA)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon